

Please amend the above-identified application as set forth below.

IN THE SPECIFICATION

Please insert following paragraph between "The Title of the Invention" and "BACKGROUND OF THE INVENTION"

--CROSS-REFERENCE TO RELATED APPLICATIONS

B1 This application is a continuation-in-part of U.S. application Serial No. 09/993,003 filed on November 6, 2001, which is currently pending.--

REMARKS

Claims 1-37 are currently pending in the present application.

The specification has been amended to insert a reference to the parent application in order to comply with the requirements of 35 U.S.C. §120 for claiming the benefit of an earlier-filed U.S. patent application.

The Restriction Requirement

In response to the Office Action dated July 2, 2002, and the restriction requirement made in the Office Action dated April 23, 2002, Applicant provisionally elects Group 1, claims 1-20, for initial examination on the merits with traverse.

✓20 In support of the restriction requirement, the Examiner alleges that the process as claimed in claims 1-2 can be practiced with another materially different product, alleging that interleukin-1- α derivatives can be used in the method claimed in claims 1-20. The applicant traverses the requirement on the basis that claims 1-20 specifically require the use of the composition of claims 21-37 in the method of claims 1-20. Accordingly, interleukin-1- α derivatives cannot be used in the process, as claimed, since the process, as claimed, requires the use of the composition of claims 21-37.